Enlivex Therapeutics Ltd. (ENLV)
NASDAQ
Market Cap
$27.05M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
652 of 958
Rank in Industry
363 of 549
Largest Insider Buys in Sector
ENLV Stock Price History Chart
ENLV Stock Performance
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Insider Activity of Enlivex Therapeutics Ltd.
Over the last 12 months, insiders at Enlivex Therapeutics Ltd. have bought $0 and sold $0 worth of Enlivex Therapeutics Ltd. stock.
On average, over the past 5 years, insiders at Enlivex Therapeutics Ltd. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Enlivex Therapeutics Ltd.
| 2015-10-09 | Sale | former SVP - Operations | 56,390 0.6424% | $2.78 | $156,764 | -52.92% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.